BIOE Bio Essence Corp
Pharmaceutical Preparations · OTC · SEC CIK 1723059 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY435.2%
TTM net income YoY943.9%
TTM EPS YoY—
Revenue 3-yr CAGR46.9%
Net income 3-yr CAGR—
Margins
Gross margin68.4%
Operating margin45.1%
Net margin44.7%
FCF margin—
EBITDA margin54.3%
Returns
ROE—
ROA64.7%
ROIC (approx.)—
Asset turnover1.45x
Leverage & solvency
Liabilities / assets42.7%
Debt / equity0.02x
Current ratio0.17x
Interest coverage-286.41x
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio39.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.90M | $323,940 |
| Cost of revenue | $469,153 | $106,863 |
| Gross profit | $1.43M | $217,077 |
| SG&A expense | $497,809 | $676,515 |
| Operating income | $900,011 | -$459,438 |
| Interest expense | $2,186 | $2,153 |
| Pretax income | $896,997 | -$1.56M |
| Income tax | $800 | $800 |
| Net income | $896,197 | -$1.31M |
| EBITDA | $900,246 | -$458,527 |
| EPS (basic) | — | -0.03 |
| EPS (diluted) | — | -0.03 |
| Weighted avg. shares (diluted) | 38.01M | 38.01M |
| Balance sheet | ||
| Cash & equivalents | — | $1,371 |
| Receivables | $23,454 | $5,124 |
| Current assets | $422,377 | $280,692 |
| Intangibles | $97 | $332 |
| Total assets | $422,474 | $281,024 |
| Current liabilities | $2.44M | $2.80M |
| Long-term debt | $57,482 | $56,481 |
| Total debt | $57,482 | $56,481 |
| Total liabilities | $2.50M | $3.25M |
| Shareholders' equity | -$2.07M | -$2.97M |
| Net debt | — | $55,110 |
| Shares outstanding | 38.01M | 38.01M |
| Cash flow statement | ||
| Operating cash flow | $1.57M | $623,865 |
| Investing cash flow | — | -$114 |
| Financing cash flow | -$1.57M | -$622,494 |
| Depreciation & amortization | $235 | $911 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.